The Elekta Esteya^® electronic brachytherapy system in non-melanoma skin cancers: A post-market observational study.

ABSTRACT:

Purpose

The study was conducted to provide support for the delivery of electronic brachytherapy (EBx) in patients with low-risk non-melanoma skin cancer (NMSC) lesions who prefer and benefit a non-surgical treatment.

Material and methods

This study included 205 patients with a total of 236 lesions. Six centers participated in this study using high-dose-rate EBx in NMSC. Eligible patients had pathologically confirmed basal cell or squamous cell carcinoma of clinical stage Tis, T1, or T2, with two or fewer high-risk clinical or pathologic features. Treatment doses were chosen from a set of fractionation schemes delivering 69-72 Gy (BED). Maximum follow-up was 5 years.

Results

The median age was 74 (range, 56-96) years, and 62% of the subjects were males and 38% females.

SUBMITTER: Cheng J 

PROVIDER: S-EPMC11812133 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature